AU2003284111A8 - Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol - Google Patents

Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol

Info

Publication number
AU2003284111A8
AU2003284111A8 AU2003284111A AU2003284111A AU2003284111A8 AU 2003284111 A8 AU2003284111 A8 AU 2003284111A8 AU 2003284111 A AU2003284111 A AU 2003284111A AU 2003284111 A AU2003284111 A AU 2003284111A AU 2003284111 A8 AU2003284111 A8 AU 2003284111A8
Authority
AU
Australia
Prior art keywords
hdl cholesterol
dose effects
gene haplotypes
atorvastatin dose
itgb3 gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003284111A
Other versions
AU2003284111A1 (en
Inventor
Helen H Lee
Karen M Bieglecki
David P Russo
Steven C Bentivegna
Chad Messer
Andreas K Windemuth
Richard S Judson
Michael Lachowicz
Eileen M Rounds
Carlos D Brain
Carol R Reed
Bradley J Dain
Lynne Litvyn
Gina-Marie Cappola
Nathan Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cogenics Inc
Original Assignee
Genaissance Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaissance Pharmaceuticals Inc filed Critical Genaissance Pharmaceuticals Inc
Publication of AU2003284111A1 publication Critical patent/AU2003284111A1/en
Publication of AU2003284111A8 publication Critical patent/AU2003284111A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003284111A 2002-10-09 2003-10-09 Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol Abandoned AU2003284111A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41774302P 2002-10-09 2002-10-09
US60/417,743 2002-10-09
PCT/US2003/032361 WO2004033710A2 (en) 2002-10-09 2003-10-09 Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol

Publications (2)

Publication Number Publication Date
AU2003284111A1 AU2003284111A1 (en) 2004-05-04
AU2003284111A8 true AU2003284111A8 (en) 2004-05-04

Family

ID=32094078

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003284111A Abandoned AU2003284111A1 (en) 2002-10-09 2003-10-09 Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol

Country Status (2)

Country Link
AU (1) AU2003284111A1 (en)
WO (1) WO2004033710A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110010824A (en) 2003-01-14 2011-02-07 아레나 파마슈티칼스, 인크. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
JP4920410B2 (en) 2003-07-14 2012-04-18 アリーナ ファーマシューティカルズ， インコーポレイテッド Fused aryl and heteroaryl derivatives as metabolic modulators and prevention and treatment of metabolic-related disorders
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
MX2021011472A (en) 2015-01-06 2022-08-17 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor.
KR102603199B1 (en) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta for use in S1P1 receptor-related disorders [Ｂ]Indole-3-yl)crystalline L-arginine salt of acetic acid (Compound 1)
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface

Also Published As

Publication number Publication date
AU2003284111A1 (en) 2004-05-04
WO2004033710A3 (en) 2004-11-18
WO2004033710A2 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
IL164760A0 (en) Transdermal analgesic systems with reduced abuse potential
AU2003205950A1 (en) Placement of alternative advertisements
AU2003272227A1 (en) Patient support system and elements thereof
AU2003203029A1 (en) Improved health-related devices and methods
AU2003258195A1 (en) Modular computer system and components therefor
EP1490074A4 (en) Mixed- cell gene therapy
AU2003209226A1 (en) Adiponectin gene therapy
AU2003235956A1 (en) Quinazoline derivative and medicine
AU2003232821A1 (en) Novel phospholipases and uses thereof
AU2003284111A8 (en) Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
AU2003201863A1 (en) Potential therapeutic device
EP1434875A4 (en) Gene polymorphisms and response to treatment
AU2003251513A1 (en) Rsk inhibitors and therapeutic uses thereof
EP1496122A4 (en) Novel meloidogyne-resistance gene and utilization thereof
AUPS271902A0 (en) Gene expression and multiple sclerosis
AU2002953223A0 (en) Novel therapeutic molecules and uses thereof
AU2003201159A1 (en) Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
AU2002951611A0 (en) Cholesterol efflux and uses thereof
AU2003213272A1 (en) Electronic floor display cleaning system and protective cover
AU2002953516A0 (en) Genetic therapy and genetic modification
AU2003228990A8 (en) Hydroxyphosphonates and phosphonophosphates as apolipoprotein e modulators
AU2003202553A1 (en) Genetic polymorphisms predicting cardiovascular disease and medication efficacy
AU2003252991A1 (en) INTERFERON-Alpha INDUCED GENE
GB0229139D0 (en) Gene polymorphisms
AUPS283302A0 (en) Therapeutic molecules and methods - 2

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase